miR-378a-3p mimic

miR-378a-3p mimic is a synthetic microRNA (miRNA) oligonucleotide designed to replenish the levels of endogenous miR-378a-3p, which is significantly downregulated in the intestinal mucosa of patients with active Crohn's disease. Developed by researchers at Chung-Ang University, this RNA therapy acts as an anti-inflammatory agent by post-transcriptionally silencing pro-inflammatory targets, specifically Interleukin-33 (IL-33) and Metastasis-associated in colon cancer 1 (MACC1). In preclinical models of dextran sodium sulfate (DSS)-induced colitis, administration of the mimic demonstrated therapeutic potential by reducing body weight loss, colon inflammation, and immune cell infiltration. The mechanism involves an IL-33 pathway-dependent anti-inflammatory response and the regulation of gut inflammation through the inhibition of MACC1 gene expression, which also appears to modulate the fecal microbiome by promoting beneficial bacterial species.

Other names

microRNA-378a-3p mimicmicroRNA378a-3p mimicmicroRNA 378a-3p mimichsa-miR-378a-3p mimichsa-miR378a-3p mimichsa-miR 378a-3p mimic